Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11335727 
Mayo LD, et al. (2001) Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J Biol Chem 276, 25184-9 11335727
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S63-p - ATF-1 (human)
Orthologous residues
ATF‑1 (human): S63‑p, ATF‑1 (mouse): S63‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
GF109203X VEGF inhibit treatment-induced increase
K252a VEGF no effect upon treatment-induced increase
H-89 VEGF no effect upon treatment-induced increase
LY294002 VEGF no effect upon treatment-induced increase
SB202190 VEGF inhibit treatment-induced increase
PD98059 VEGF no effect upon treatment-induced increase
SU5416 VEGF inhibit treatment-induced increase
SB202190 no change compared to control
GF109203X no change compared to control
PlGF no change compared to control

S133-p - CREB (human)
Orthologous residues
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
SU5416 VEGF inhibit treatment-induced increase
PD98059 VEGF no effect upon treatment-induced increase
SB202190 VEGF inhibit treatment-induced increase
LY294002 VEGF no effect upon treatment-induced increase
H-89 VEGF no effect upon treatment-induced increase
GF109203X VEGF inhibit treatment-induced increase
SB202190 no change compared to control
GF109203X no change compared to control
PlGF no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.